Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Notes Payables (2021 - 2026)

bioAffinity Technologies has reported Notes Payables over the past 5 years, most recently at $61141.0 for Q1 2026.

  • Quarterly Notes Payables fell 41.64% to $61141.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $61141.0 through Mar 2026, down 41.64% year-over-year, with the annual reading at $105161.0 for FY2025, 38.74% down from the prior year.
  • Notes Payables was $61141.0 for Q1 2026 at bioAffinity Technologies, down from $105161.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $325000.0 in Q3 2022 and troughed at $4106.0 in Q2 2024.
  • The 4-year median for Notes Payables is $104963.5 (2025), against an average of $121295.2.
  • The largest YoY upside for Notes Payables was 2135.72% in 2025 against a maximum downside of 48.93% in 2025.
  • A 4-year view of Notes Payables shows it stood at $325000.0 in 2022, then plummeted by 47.18% to $171669.0 in 2024, then crashed by 38.74% to $105161.0 in 2025, then crashed by 41.86% to $61141.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Notes Payables are $61141.0 (Q1 2026), $105161.0 (Q4 2025), and $136396.0 (Q3 2025).